In response to the development of radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA), nanotechnology-based delivery systems with various payloads are being explored for potential use in PCa-targeted imaging, treatment, and therapeutic applications [26, 27]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.